Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections

Aaron Matlock, Joshua Allan Garcia, Kayvan Moussavi, Brit Long, Stephen Yuan Tung Liang

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.

Original languageEnglish
Pages (from-to)2231-2241
Number of pages11
JournalInternal and Emergency Medicine
Issue number8
StatePublished - Nov 2021


  • Antibiotics
  • Multidrug-resistant
  • Novel
  • Resistance


Dive into the research topics of 'Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections'. Together they form a unique fingerprint.

Cite this